BriaCell Therapeutics (FRA:8BT) Cyclically Adjusted Book per Share: €54.49 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8BT BriaCell Therapeutics Corp FRA:8BT
38 GF Score
Price €3.54
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics Cyclically Adjusted Book per Share?

BriaCell Therapeutics FRA:8BT +19.59% 38 Cyclically Adjusted Book per Share is €54.49 as of Apr. 2026. GuruFocus rates FRA:8BT with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BriaCell Therapeutics's adjusted book value per share for the three months ended in Apr. 2026 was €2.752. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €54.49 for the trailing ten years ended in Apr. 2026.

During the past 12 months, BriaCell Therapeutics's average Cyclically Adjusted Book Growth Rate was -36.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -19.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BriaCell Therapeutics was -1.20% per year. The lowest was -25.70% per year. And the median was -16.40% per year.

As of today (2026-09-19), BriaCell Therapeutics's current stock price is €3.54. BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2026 was €54.49. BriaCell Therapeutics's Cyclically Adjusted PB Ratio of today is 0.06.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BriaCell Therapeutics was 0.04. The lowest was 0.00. And the median was 0.00.


BriaCell Therapeutics  (FRA:8BT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BriaCell Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.54/54.494
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BriaCell Therapeutics was 0.04. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BriaCell Therapeutics Cyclically Adjusted Book per Share Related Terms


BriaCell Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics Cyclically Adjusted Book per Share Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,760.33 2,522.39 301.58 122.73 53.49

BriaCell Therapeutics Quarterly Data
Jan21 Apr21 Oct21 Jan22 Apr22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.71 53.49 53.62 53.52 54.49

FRA:8BT vs VRTX, REGN, MRNA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:8BT
38GF Score
BriaCell Therapeutics Corp FRA:8BT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Apr. 2026 was:

Adj_Book= Book Value per Share /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=2.752/132.7364*132.7364
=2.752

Current CPI (Apr. 2026) = 132.7364.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201601 254.521 100.184 337.220
201604 489.894 101.370 641.483
201607 347.488 101.844 452.894
201610 663.048 102.002 862.836
201701 569.209 102.318 738.434
201704 614.336 103.029 791.476
201707 269.475 103.029 347.176
201710 337.504 103.424 433.160
201801 151.729 104.056 193.550
201804 555.317 105.320 699.874
201807 228.898 106.110 286.336
201810 88.970 105.952 111.461
201901 -144.965 105.557 -182.291
201904 131.614 107.453 162.582
201907 -132.615 108.243 -162.623
201910 -1.015 107.927 -1.248
202001 -423.690 108.085 -520.321
202004 -522.266 107.216 -646.579
202007 -579.720 108.401 -709.861
202010 -561.581 108.638 -686.150
202101 -566.584 109.192 -688.756
202104 228.013 110.851 273.031
202110 467.129 113.695 545.363
202201 400.254 114.801 462.785
202204 419.798 118.357 470.802
202210 101.071 121.517 110.403
202301 -11.398 121.596 -12.442
202304 -51.590 123.571 -55.416
202307 -32.154 124.914 -34.167
202310 22.344 125.310 23.668
202401 -71.867 125.072 -76.271
202404 -54.712 126.890 -57.233
202407 -20.355 128.075 -21.096
202410 14.178 127.838 14.721
202501 10.533 127.443 10.971
202504 16.018 129.102 16.469
202507 8.039 130.290 8.190
202510 4.300 130.603 4.370
202601 3.503 130.366 3.567
202604 2.752 132.736 2.752

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €54.49 mean?
BriaCell Therapeutics (FRA:8BT) has a Cyclically Adjusted Book per Share of €54.49 as of Apr. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BriaCell Therapeutics and its competitors.
Is BriaCell Therapeutics' Cyclically Adjusted Book per Share too high?
BriaCell Therapeutics' current Cyclically Adjusted Book per Share is €54.49. Overall, BriaCell Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' Cyclically Adjusted Book per Share compare to VRTX and REGN?
BriaCell Therapeutics' Cyclically Adjusted Book per Share of €54.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current Cyclically Adjusted Book per Share is €54.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (FRA:8BT) has a current Cyclically Adjusted Book per Share of €54.49. The current Cyclically Adjusted Book per Share is €54.49. BriaCell Therapeutics' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BriaCell Therapeutics (FRA:8BT), the current Cyclically Adjusted Book per Share is €54.49 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BriaCell Therapeutics Business Description

Other Exchanges BCTX:USABCT:Canada
Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
38GF Score

Get the complete analysis for FRA:8BT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.54
Price